Back to search results

A Study on Taking an Additional Dose of Rimegepant for Migraine

This study is looking into the safety of taking an additional dose of rimegepant, a medication for acute migraine attacks. Sometimes, the first dose of migraine medicine might not fully relieve pain, and a second dose could be helpful. This study wants to see if taking a second dose of rimegepant is safe and well-tolerated. Researchers will be monitoring for any side effects (adverse events) and changes in liver function tests (LFTs) over six months. You might be able to join if you are an adult, 18 years or older, with at least a one-year history of migraine and are currently using acute migraine treatment. The study aims to enroll about 400 participants, but its current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment (rimegepant). It plans to include about 400 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will monitor participants for up to 6 months to track side effects and liver function.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07609914

A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

Recruiting
PHASE4Ages 18+InterventionalTreatment
Pfizer
~400 participants
Updated 2026-08-24 on ClinicalTrials.gov
What's tested:Rimegepant

At a glance

Recruiting sites
11 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Treatment-Emergent Adverse Events (TEAEs), serious TEAEs, and TEAEs leading to study intervention discontinuation on treatment by average monthly redosing frequency over the entire OLT phase (<3, ≥3 to <6, ≥6 re-doses per month) and overall
Measured over Up to 6 months
+1 more outcome measured

Conditions

Acute Treatment of Migraine

Explore related trials

Migraine

Where it's being run

14 sites across 10 states
Florida3
California2
Texas2
Massachusetts1
Michigan1
Mississippi1
North Carolina1
Virginia1

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

Pfizer CT.gov Call Center
[email protected]
1-800-718-1021
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of Treatment-Emergent Adverse Events (TEAEs), serious TEAEs, and TEAEs leading to study intervention discontinuation on treatment by average monthly redosing frequency over the entire OLT phase (<3, ≥3 to <6, ≥6 re-doses per month) and overallUp to 6 months
  • Incidence of LFT elevations, AST >3x ULN, alanine aminotransferase ALT >3x ULN, and total bilirubin >2x ULN on treatment by average monthly redosing frequency over the entire OLT phase (<3, ≥3 to <6, ≥6 re-doses per month) and overallUp to 6 months